Suppr超能文献

fremanezumab治疗药物过度使用所致偏头痛的系统评价

Fremanezumab for the Treatment of Migraine Complicated by Medication Overuse: A Systematic Review.

作者信息

Hajjaj Ibrahim, Baraldi Carlo, Pellesi Lanfranco

机构信息

Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, Campusvej 55, 5230, Odense, Denmark.

Azienda Unità Sanitaria Locale di Modena, Modena, Italy.

出版信息

Clin Drug Investig. 2025 May;45(5):247-254. doi: 10.1007/s40261-025-01433-y. Epub 2025 Mar 22.

Abstract

BACKGROUND

Monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway, such as fremanezumab, are effective for migraine prevention. However, their effectiveness in treating migraine complicated by medication overuse, remains underexplored.

OBJECTIVE

This systematic review aims to evaluate the effectiveness of fremanezumab in adults with migraine complicated by medication overuse.

METHODS

We systematically searched PubMed and Embase (Ovid) databases for studies on fremanezumab, selecting primary studies that included adults with migraine complicated by medication overuse and reported at least one efficacy outcome. The search was performed in January 2024 and then updated in June 2024. Risk of bias for randomized controlled trials was assessed using the Cochrane Risk of Bias 2 (RoB 2) tool, while real-world studies were evaluated using both the ROBINS-I and ROB-ME tools. Data extraction and analysis followed established guidelines.

RESULTS

Our search identified 176 records, of which 2 clinical trials and 7 real-world studies were included. Included studies recruited a total of 1422 adults with migraine complicated by medication overuse. In post hoc analyses from clinical trials, fremanezumab significantly reduced monthly migraine days, days with acute headache medication use, and Headache Impact Test (HIT-6) scores compared to placebo during a 12-week period. The real-world studies reported a reduction in monthly headache days at 6 months, and a high reversion rate from medication overuse headache (MOH) after one year of treatment.

CONCLUSION

Both post hoc analyses from clinical trials and real-world studies support fremanezumab benefits in reducing migraine frequency, medication use, and headache-related disability in adults with migraine complicated by medication overuse. Given the limited quality of data, further real-world research with standardized reporting criteria is needed to substantiate long-term benefits and establish optimal treatment protocols.

摘要

背景

靶向降钙素基因相关肽(CGRP)途径的单克隆抗体,如夫瑞吉单抗,对偏头痛预防有效。然而,其在治疗药物过度使用所致偏头痛方面的有效性仍未得到充分研究。

目的

本系统评价旨在评估夫瑞吉单抗在药物过度使用所致偏头痛成人患者中的有效性。

方法

我们系统检索了PubMed和Embase(Ovid)数据库中关于夫瑞吉单抗的研究,选择纳入药物过度使用所致偏头痛成人患者且报告至少一项疗效结果的原始研究。检索于2024年1月进行,随后在2024年6月更新。使用Cochrane偏倚风险2(RoB 2)工具评估随机对照试验的偏倚风险,而使用ROBINS-I和ROB-ME工具评估真实世界研究。数据提取和分析遵循既定指南。

结果

我们的检索共识别出176条记录,其中纳入了2项临床试验和7项真实世界研究。纳入研究共招募了1422例药物过度使用所致偏头痛成人患者。在临床试验的事后分析中,与安慰剂相比,夫瑞吉单抗在12周期间显著减少了每月偏头痛天数、使用急性头痛药物的天数以及头痛影响测试(HIT-6)评分。真实世界研究报告称,在6个月时每月头痛天数减少,且在治疗一年后药物过度使用性头痛(MOH)的逆转率较高。

结论

临床试验的事后分析和真实世界研究均支持夫瑞吉单抗在降低药物过度使用所致偏头痛成人患者的偏头痛频率、药物使用和头痛相关残疾方面的益处。鉴于数据质量有限,需要进一步开展具有标准化报告标准的真实世界研究,以证实长期益处并建立最佳治疗方案。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验